The ALK fusion mutation‐targeted drug ALK‐TKIs (ALK‐tyrosine kinase inhibitors), an ATP‐competitive small molecule inhibitor of tyrosine kinases, can significantly improve the prognosis of NSCLC patients with ALK fusion mutation, whose median progression‐free survival (mPFS) was improved from 7–8.1 months to 10.4–28.5 months [17, 22, 23, 27, 39, 40, 41, 42, 43, 44]. This evidence concerns the gene ALK and non-small cell lung carcinoma.